Kathmere Capital Management LLC Raises Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Kathmere Capital Management LLC increased its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 83.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,290 shares of the company's stock after purchasing an additional 4,232 shares during the period. Kathmere Capital Management LLC's holdings in AstraZeneca were worth $683,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Cibc World Markets Corp grew its stake in shares of AstraZeneca by 1.1% during the 4th quarter. Cibc World Markets Corp now owns 12,901 shares of the company's stock valued at $845,000 after acquiring an additional 142 shares during the period. Principal Securities Inc. grew its stake in shares of AstraZeneca by 0.5% during the 1st quarter. Principal Securities Inc. now owns 28,053 shares of the company's stock valued at $2,062,000 after acquiring an additional 142 shares during the period. CoreCap Advisors LLC grew its stake in shares of AstraZeneca by 31.8% during the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock valued at $42,000 after acquiring an additional 155 shares during the period. Oakworth Capital Inc. grew its stake in shares of AstraZeneca by 2.0% during the 1st quarter. Oakworth Capital Inc. now owns 8,575 shares of the company's stock valued at $630,000 after acquiring an additional 167 shares during the period. Finally, Spinnaker Investment Group LLC grew its stake in shares of AstraZeneca by 3.1% during the 1st quarter. Spinnaker Investment Group LLC now owns 5,754 shares of the company's stock valued at $423,000 after acquiring an additional 174 shares during the period. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Price Performance

NASDAQ AZN traded down $0.68 during trading hours on Friday, reaching $71.13. The company's stock had a trading volume of 2,729,851 shares, compared to its average volume of 5,279,228. The firm's 50-day moving average price is $70.72 and its 200-day moving average price is $70.81. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $87.68. The company has a market capitalization of $220.60 billion, a price-to-earnings ratio of 28.57, a PEG ratio of 1.31 and a beta of 0.37.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The company had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. During the same period in the previous year, the firm earned $2.06 EPS. The firm's revenue was up 7.2% compared to the same quarter last year. On average, equities research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Berenberg Bank set a $97.00 price objective on AstraZeneca in a research note on Wednesday. BNP Paribas began coverage on AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of "Moderate Buy" and an average price target of $89.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.